CD79A-directed nanobody therapeutics for drug-resistant b-cell lymphomas
Active Project Grant Awarded Last action
- Award ID
- HT9425261E323
- Recipient
-
The Geneva Foundation UEI TR9RX33188T4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $547,103
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 3% complete
- Place of performance
- Tacoma, WA 98402, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded The Geneva Foundation $547,103 on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop CD79A-directed nanobody therapeutics for drug-resistant B-cell lymphomas. Work will be performed in Tacoma, Washington, through September 29, 2028. The Geneva Foundation is a 501(c)(3) nonprofit research organization that serves as a prime recipient on federal biomedical research and clinical support services, with the Defense Health Agency and Department of the Army Medical Command dominating its customer base. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for service members and the American public through innovative research and investigation of medical solutions for the battlefield.
Quick answers
Who received award HT9425261E323?
HT9425261E323 was awarded to The Geneva Foundation by Defense Health Agency (Department of Defense) on September 30, 2026.
How much is award HT9425261E323 worth?
$547,103 has been obligated on HT9425261E323.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award